DCC-interacting protein 13-beta (APPL2) (APPL2)

DCC-interacting protein 13-beta (APPL2) mRNA is the transcript encoding the APPL2 adapter protein, which is a critical regulator of endosomal signaling and intracellular trafficking [1]. The encoded protein contains BAR, PH, and PTB domains that allow it to interact with signaling lipids and receptors, such as the adiponectin receptor and the insulin receptor substrate [1, 2]. APPL2 acts as a negative regulator of insulin signaling by sequestering APPL1, thereby inhibiting Akt activation and reducing glucose uptake in metabolic tissues [3]. Consequently, elevated levels of APPL2 mRNA and protein are associated with insulin resistance, Type 2 diabetes, and obesity [3, 4]. In addition to its metabolic roles, APPL2 is involved in cell proliferation and survival pathways, suggesting potential implications in oncology [1]. Therapeutic strategies targeting APPL2 mRNA, such as antisense oligonucleotides or siRNA, aim to reduce APPL2 protein expression to enhance insulin sensitivity or inhibit pathological signaling in cancer. References: [1] UniProt (Q8NEU8); [2] Mao et al. (2006) Nat Cell Biol; [3] Cheng et al. (2012) Diabetes; [4] Wang et al. (2009) J Biol Chem.

Other names

DIP13BAdapter protein containing PH domain, SH3 domain and phosphotyrosine binding domain 2APPL2DCC-interacting protein 13-beta

The primary mechanism of action for targeting APPL2 mRNA involves the use of antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) to induce sequence-specific degradation of the transcript or inhibit its translation, thereby reducing the cellular levels of the APPL2 protein and modulating downstream signaling pathways such as Akt and MAPK.